Status:
TERMINATED
Low-dose Cortisol in Chronic Posttraumatic Stress Disorder
Lead Sponsor:
University of Zurich
Conditions:
Posttraumatic Stress Disorder
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
The aim of this prospective, double-blind, placebo-controlled, cross-over study is to determine the therapeutic efficacy of low-dose cortisol for symptoms of chronic posttraumatic stress disorder.
Eligibility Criteria
Inclusion
- Female and male patients with chronic PTSD due to adult trauma; PTSD is diagnosed according to the DSM-IV, as measured with the CAPS
- Age between 18 and 60
Exclusion
- History of disease states representing contraindications to glucocorticoid therapy (tuberculosis, gastritis, gastric- and duodenal ulcers, Cushing's disease, osteoporosis, hypertension, pregnancy (to exclude with a pregnancy test) and lactation, glaucoma, diabetes mellitus, thrombophilia, acute or chronic infections, hyperthyroidism, cirrhosis)
- Severe or chronic somatic diseases
- Topic glucocorticoid therapy (for large skin parts)
- Inhaled glucocorticoids
- Current psychotic, bipolar, substance-related, or severe personality disorder
- Current severe depressive disorder
- Severe cognitive impairment or a history of organic mental disorder
- Evidence of PTSD or depression immediately prior to the index trauma
- Prominent current suicidal or homicidal ideation
- Asylum seeking status
- Body weight \>20% above or below normal range
- Changes in psychopharmacologic or psychotherapeutic management less than 8 weeks before start of the study
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2009
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00362661
Start Date
June 1 2007
End Date
December 1 2009
Last Update
January 12 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Psychiatry, University Hospital Zurich
Zurich, Switzerland, 8091